Wall Street analysts expect Stryker Co. (NYSE:SYK) to post $1.60 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Stryker’s earnings, with the highest EPS estimate coming in at $1.64 and the lowest estimate coming in at $1.58. Stryker reported earnings of $1.48 per share during the same quarter last year, which would suggest a positive year over year growth rate of 8.1%. The business is scheduled to issue its next earnings results on Tuesday, April 24th.
On average, analysts expect that Stryker will report full year earnings of $7.12 per share for the current financial year, with EPS estimates ranging from $7.08 to $7.17. For the next financial year, analysts forecast that the firm will report earnings of $7.82 per share, with EPS estimates ranging from $7.69 to $7.95. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Stryker.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The business had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the firm posted $1.78 earnings per share. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year.
Several research analysts have recently commented on SYK shares. Zacks Investment Research raised shares of Stryker from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Robert W. Baird reissued a “hold” rating and issued a $161.00 price objective on shares of Stryker in a research note on Friday, October 27th. Piper Jaffray Companies reissued a “buy” rating and issued a $156.00 price objective on shares of Stryker in a research note on Friday, October 27th. Wells Fargo & Co raised their price objective on shares of Stryker from $160.00 to $166.00 in a research note on Friday, October 27th. Finally, Stifel Nicolaus raised their target price on shares of Stryker from $158.00 to $168.00 and gave the company a “buy” rating in a report on Friday, October 27th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. Stryker presently has a consensus rating of “Hold” and an average price target of $162.50.
Stryker (NYSE:SYK) traded down $1.55 during midday trading on Tuesday, hitting $158.32. 214,188 shares of the stock traded hands, compared to its average volume of 1,423,516. The company has a current ratio of 2.29, a quick ratio of 1.59 and a debt-to-equity ratio of 0.66. Stryker has a twelve month low of $126.00 and a twelve month high of $170.00. The stock has a market capitalization of $59,890.00, a price-to-earnings ratio of 59.07, a price-to-earnings-growth ratio of 2.30 and a beta of 0.70.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be issued a dividend of $0.47 per share. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.19%. Stryker’s payout ratio is currently 70.15%.
In other Stryker news, Director Howard E. Cox, Jr. sold 7,400 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $164.09, for a total transaction of $1,214,266.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP William E. Berry, Jr. sold 1,306 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total transaction of $214,732.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,840 shares of company stock worth $2,749,989. 7.40% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. William Blair Investment Management LLC purchased a new position in shares of Stryker during the fourth quarter worth approximately $32,421,000. HM Payson & Co. grew its position in shares of Stryker by 9.4% during the fourth quarter. HM Payson & Co. now owns 7,346 shares of the medical technology company’s stock worth $1,138,000 after acquiring an additional 630 shares during the last quarter. Banco de Sabadell S.A purchased a new position in shares of Stryker during the fourth quarter worth approximately $1,906,000. Lake Street Advisors Group LLC purchased a new position in shares of Stryker during the fourth quarter worth approximately $364,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Stryker during the fourth quarter worth approximately $15,419,000. 74.49% of the stock is currently owned by institutional investors.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.